Events on 27 September 2023

CONGRESS 2023 - Can a laboratory investigate allergic reactions to COVID vaccines?

Vaccinations to Covid 19 virus have been at the forefront of news headlines. One of the issues highlighted was the risk of adverse reactions, both allergic and non-allergic. This caused an influx of queries to Allergy services regarding patients who had suffered potential allergic reactions and posed the question, 'how can they be investigated'?

The laboratory has limited commercial assays to the components and excipients of vaccines. However, tests can potentially be modified or developed in-house to provide evidence of a potential allergy. They could also be utilised to determine if an alternative vaccination can be used. The testing strategy may need to be adapted on a case by case basis.

There is the potential that this could be used to develop a service for allergic reaction investigation for all vaccine types.

CONGRESS 2023 - Interpretation of ISAC

Interpretation of ISAC

CONGRESS 2023 - Vaccines and immunodeficiency testing (Wednesday)

A person's immune response to previous antigen exposure is one of the most useful measures of how well their immune system is functioning. Vaccination provides a controlled and standardised exposure to an antigen, with the ability to assess immune responses prior to and after exposure. Different vaccine types can be used to explore different aspects of immune function.

Traditionally, antibody levels have been used to interrogate these responses, and it is possible to explore the quality of the antibody response and also cellular responses. A wide variability in the response to vaccination in healthy individuals can complicate interpretation of vaccine responses in patients with recurrent infections. Protection from infection is multifactorial, and while our ability to assess vaccine responses is improving, this alone is often not enough to assess an individual's immunity.

CONGRESS 2023 - Clinical Liaison Role in Wales – an update on the journey so far

Clinical Liaison Role in Wales – an update on the journey so far

CONGRESS 2023 - The ringworm turns: The emergence of Trichophyton indotineae in the UK

Trichophyton indotinaea is a newly described species of dermatophyte that has emerged with the last 10 years in India, and some Middle Eastern countries. It causes tinea corporis and tinea cruris mainly (ringworm infection of the torso and groin) and can spread to the arms, legs and face. T. indotineae is also characterised by a reduced susceptibility or outright resistance to one of the commonly used and otherwise highly effective antifungals, terbinafine. While high levels of cases are seen in Indida, countries outside of India and the Middle East are now seeing imported cases and the UK is not alone. Working with colleagues in London we have identified signficant numbers of cases and are now understanding how difficult these infections are to treat, even with antifungals that the organism should be sensitive to. Lesions are only superficial, but are itchy and disfiguring, and often relapse after initial antifungal therapy. We are continuing to learn about the epidemiology, transmission, diagnosis and treatment of this emerging infection.

CONGRESS 2023 - FMT/NICE guidance

Clostridioides difficile is responsible for the eponymous C. difficile infection (CDI). Faecal microbiota transplant (FMT), a NICE recommended treatment for recurrent CDI, is effective but logistic and safety concerns remain.

With the advent of non-donor derived products, the presentation will outline the principles and evidence related to correcting gut dysbiosis and explore whether there is a need for current or expanded FMT services in the future.

CONGRESS 2023 - Recent increases in diphtheria cases in England

Diphtheria is a potentially fatal disease caused by strains of Corynebacterium diphtheriae, C. ulcerans or C. pseudotubercolosis that express the diphtheria toxin. It can present as a respiratory infection or as non-healing skin wounds. Diphtheria was historically most likely to be caused by C. diphtheriae. It is very rare in England (typically <10 cases per year) due to a successful routine immunisation programme. However, there has been a recent gradual increase in cases over several years, particularly cutaneous infections and those caused by toxigenic C. ulcerans strains (which can be carried by household pets).

In 2022, there was a particulary large increase in diphtheria in England, with 87 cases and 3 deaths. This included 72 toxigenic C. diphtheriae infections in asylum seekers, thought to be aquired during their travel to the UK. Symptoms ranged from severe respiratory diphtheria to cutaneous infections and asymptomatic carriage. Similar increases of C. diphtheriae infections in travelling migrants have been seen in several European countries. Some of these isolates are multidrug resistant, including to macrolides, the default recommendation for treatment, and this will require careful monitoring.

CONGRESS 2023 - It’s life, but not as we know it. Emerging parasitic diseases

It’s life, but not as we know it. Emerging parasitic diseases

CONGRESS 2023 - Neonatal Meningitis

This presentation will outline the content of Paola's Clincal Case Study from her Higher Specialist Portfolio in Medical Microbiology. Here she will present the initial clinical presentation, diagnosis and treatment of a case of neonatal sepsis that linked to a previous unusual maternal screening swab. She will also outline her experience of the Higher Specialist Diploma and her plans for developing a training plan within Microbiology QMC, Nottingham for future candidates within their trust.

CONGRESS 2023 - Rat Bite Fever

This presentation is based on a case study used for a portfolio of Higher Specialist Diploma awarded by the IBMS. The presentation will look at how blood cultures taken on admission helped with diagnosis and appropriate treatment of a patient. It will also go in to brief detail on the organism isolated, Streptobacillus moniliformis.
  1. 2
  2. 3
  3. 4
  4. 5
  5. 6
  6. 7
  7. 8
  8. 9
  9. 10
  10. 11